
What We're Reading: FDA Approves Alzheimer Drug; Spike in Adolescent COVID-19 Hospitalization Rates; Racial Bias in Health Care
The FDA approves a new drug for Alzheimer disease; COVID-19–related hospitalization rates are on the rise among adolescents; efforts to address racism, discrimination, and implicit bias in health care; the United States will send 1 million Johnson & Johnson COVID-19 vaccines to Mexico cities along the border and resorts.
FDA Approves New Alzheimer Disease Treatment
The FDA issued an approval for Biogen’s aducanumab (Aduhelm) for Alzheimer disease, making it the first new therapy approval in the space since 2003. Aducanumab is the first treatment to target the buildup of amyloid beta plaques in the brain, which are thought to be a pathophysiological driver of the neurodegenerative disease. Although aducanumab cannot reverse the progression of Alzheimer disease, it is expected to slow cognitive decline.
CDC Report Finds Spike in COVID-19–Related Hospitalizations in Teens
According to findings in the latest
Addressing Racial Bias in Health Care
An article from
United States to Send 1M Vaccines to Mexico Border Cities, Resorts
As reported by
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.